Table 3.

Multivariate associations between explicative factors and ABPA in people with cystic fibrosis from the French CF Registry.

	Odds ratio	95% confidence interval	P-value
Nutritional status, BMI
BMI (continuous)	0.94	[0.89; 1.00]	.0412
Low (<18.5) vs. normal (18.5–24.9)	1.05	[0.70; 1.58]	.8121
High (>25) vs. normal (18.5–24.9)	0.47	[0.24; 0.95]	.0365
Glucose disorder vs. none	1.41	[1.02; 1.93]	.0353
Respiratory status
ppFEV1 (continuous)	1.00	[1.00; 1.01]	.7745
ppFEV1 < 40% vs. ≥ 70%	0.75	[0.40; 1.40]	.3619
ppFEV1 40%–70% vs. ≥ 70%	0.90	[0.61; 1.34]	.5994
Pseudomonas aeruginosa colonization vs. none	1.31	[0.90; 1.89]	.1575
Therapy for advanced pulmonary disease (oxygen or NIV) vs. none	1.75	[0.83; 3.67]	.1384
Number of annual intravenous antibiotic courses
1–3 vs. 0	1.69	[1.19; 2.39]	.0033
>3 vs. 0	2.47	[1.21; 5.05]	.0132
Long-term inhaled corticosteroids	1.82	[1.33; 2.48]	.0002
Long-term azithromycin	1.24	[0.92; 1.67]	.1644
Antifungal treatment	5.83	[2.55; 13.35]	<.0001

Note: Significant P-values are in bold.

BMI: body mass index, ppFEV1: predicted forced expiratory volume in 1 s, NIV: noninvasive ventilation.